Marpai, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Rhea-AI Summary

Marpai, Inc. (NASDAQ: MRAI) has successfully closed its initial public offering, selling 7,187,500 shares of common stock at $4.00 each, which resulted in gross proceeds of $28.75 million, excluding underwriting discounts and offering expenses. The offering included 937,500 shares sold through the underwriters' over-allotment option. ThinkEquity served as the sole book-running manager for this offering. The company utilizes deep learning technology to improve healthcare management for self-funded markets, serving over 60 self-funded companies and 40,000 members nationwide.

Positive

• Closed initial public offering with 7,187,500 shares sold.
• Raised $28.75 million in gross proceeds.
• Deep learning technology aimed at reducing healthcare costs and improving outcomes.

Negative

• Potential dilution of shares due to public offering.

TAMPA, Fla.--(BUSINESS WIRE)-- Marpai, Inc. (the “Company”) (Nasdaq: MRAI), a deep learning technology company transforming third party administration in the healthcare self-funded market, today announced the closing of its initial public offering of 7,187,500 shares of its common stock at a public offering price of $4.00 per share, including 937,500 shares sold upon full exercise of the underwriters’ over-allotment option, for gross proceeds of $28.75 million, before deducting underwriting discounts and offering expenses.

ThinkEquity acted as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-258029) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on October 26, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Marpai, Inc.

Marpai is an AI-driven health tech company transforming third party administration in the self-funded market by deploying deep learning, an advanced form of artificial intelligence, to radically reduce costs, improve lives and simplify everything. Marpai predicts near-term health challenges to prevent illness, guides members to top quality providers for best outcomes and uses SMART automation to create efficiencies and make it easy for members to take better care of their health. Operating nationwide in serving over 60 self-funded companies and over 40,000 members, Marpai works with world class provider networks including Aetna and Cigna and partners with brokers and consultants across the U.S. For more information visit www.marpaihealth.com.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005488/en/

Dave Gentry

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

or 407-491-4498

Dave@redchip.com

Source: Marpai, Inc.

FAQ

What is the significance of Marpai Inc.'s IPO on October 29, 2021?

Marpai Inc. closed its IPO, offering 7,187,500 shares at $4.00 each, raising $28.75 million.

How many shares were sold in Marpai Inc.'s IPO?

A total of 7,187,500 shares were sold, including 937,500 shares from the underwriters' over-allotment.

Who managed Marpai Inc.'s IPO?

ThinkEquity acted as the sole book-running manager for Marpai's IPO.

What does Marpai Inc. do?

Marpai Inc. is a healthcare technology company utilizing deep learning to optimize third-party administration in the self-funded market.

What are the potential impacts of Marpai's IPO on shareholders?

Shareholders may face dilution from the public offering, but the funds raised could drive growth and innovation.